CORRESP Filing
AlphaTON Capital Corp
Date: May 12, 2025 · CIK: 0001095435 · Accession: 0001171843-25-003090
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-28696
Referenced dates: May 8, 2025
Letter
United States Securities and Exchange Commission Division of Corporation Finance – Office of Washington, DC 20549 Attention: Mr. Tim Buchmiller Re: Portage Biotech Inc. Comment Letter dated May 8, 2025 Form F-3, Amendment No. 1 File No. 333-28696
Dear Mr. Buchmiller:
Reference is made to the letter of the staff (the "Staff") of the Securities and Exchange Commission (the "Commission"), dated May 8, 2025 ("Comment Letter"), commenting on the filing of Form F-3 ("Form F-3") of Portage Biotech Inc. (the "Company"). I am responding on behalf of the Company, as its United States counsel, to the Comment Letter. The response format sets forth the Staff comment followed by the Company response thereto.
The Company has amended the Form F-3 to remove the registration of debt securities and correspondingly removed all reference to debt securities in the registration statement, legal opinion and fee table.
The Company understands that its management persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the Securities and Exchange Commission.
If you have any questions about the foregoing, please do not hesitate to contact Andrew D. Hudders of this firm at 212-907-7349 or ahudders@golenbock.com.
Very truly yours,
/S/ Golenbock Eiseman Assor Bell & Peskoe LLP
Show Raw Text
CORRESP
1
filename1.htm
Attorneys at Law | 711 Third Ave., New York, NY 10017-4014
T (212) 907-7300 | F (212) 754-0330 | www.golenbock.com
Direct Dial No.: (212) 907-7349
Direct Fax No.: (212) 754-0330
Email Address: AHudders @GOLENBOCK.COM
May 12, 2025
United States Securities and Exchange Commission
Division of Corporation Finance – Office of
Life Sciences
Washington, DC 20549
Attention: Mr. Tim Buchmiller
Re:
Portage Biotech Inc.
Comment Letter dated May 8, 2025
Form F-3, Amendment No. 1
File No. 333-28696
Dear Mr. Buchmiller:
Reference is made to the letter of
the staff (the "Staff") of the Securities and Exchange Commission (the "Commission"), dated May 8, 2025 ("Comment
Letter"), commenting on the filing of Form F-3 ("Form F-3") of Portage Biotech Inc. (the "Company"). I am
responding on behalf of the Company, as its United States counsel, to the Comment Letter. The response format sets forth the Staff comment
followed by the Company response thereto.
The Company has amended the Form F-3 to remove the registration of debt
securities and correspondingly removed all reference to debt securities in the registration statement, legal opinion and fee table.
The Company understands that its management persons are responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the
Securities and Exchange Commission.
If you have any questions about the foregoing, please do not hesitate
to contact Andrew D. Hudders of this firm at 212-907-7349 or ahudders@golenbock.com.
Very truly yours,
/S/ Golenbock Eiseman Assor Bell & Peskoe LLP
Golenbock Eiseman Assor Bell & Peskoe LLP
cc:
Ms. Andrea Park,
Chief Financial Officer